Cardinal Health Delivers 70% EPS Jump, Guides FY27 Above Long-Term Target, and Authorizes $5B Buyback
CAH sits 81% above its 52-week low of $137.75.
Summary
Cardinal Health reported Q4 FY26 GAAP EPS of $1.70 (up 70%) and non-GAAP EPS of $2.91 (up 40%), with FY27 guidance above long-term targets. The board authorized a $5.0 billion incremental share repurchase, bringing total authorization to $6.4 billion.
Updates
· SEC 10-K — The 10-K reports FY26 non-GAAP diluted EPS of $11.26 and GAAP diluted EPS of $7.23, with revenue of $254.2 billion.
· dpa-AFX — Cardinal Health declared a quarterly dividend of $0.5158 per share and provided segment outlooks: 3-5% revenue growth in Pharmaceutical and Specialty Solutions, 2-4% in Global Medical Products and Distribution, with profit growth of 8-11% and $200-$220 million, respectively.
Key Events · Earnings and Guidance · CAH
-
Q4 Earnings Beat Across the Board
GAAP diluted EPS surged 70% to $1.70; non-GAAP diluted EPS rose 40% to $2.91, including a $0.31 IEEPA tariff refund benefit. Revenue grew 6% to $63.7 billion.
-
FY27 Guidance Above Long-Term Target
Non-GAAP EPS guidance of $12.40–$12.60 implies 13–15% growth, exceeding the company's long-term EPS growth target. All segments are expected to grow profit.
-
$5.0 Billion Incremental Buyback Authorized
The board approved a $5.0 billion increase to the share repurchase program, bringing total authorization to $6.4 billion. An additional $350 million accelerated buyback was completed in FY26, totaling $1.4 billion for the year.
-
Capital Structure Simplification
A new $4.0 billion revolving credit facility replaces three historic facilities, and a long-term renewal of the Kroger wholesaler distribution contract was announced.
Analysis · CAH · Trade & Services
A standout quarter saw GAAP EPS climb 70% to $1.70 and non-GAAP EPS rise 40% to $2.91, fueled by broad-based strength across all five operating segments. FY26 non-GAAP EPS of $11.26 exceeded expectations, and the FY27 guidance of $12.40–$12.60 implies 13–15% growth, outpacing the company's long-term target. The board authorized a $5.0 billion incremental share repurchase, lifting the total authorization to $6.4 billion, and completed an additional $350 million accelerated buyback. A new $4.0 billion revolving credit facility simplifies the capital structure, while the long-term renewal of the Kroger contract secures a key distribution relationship. Together, the results and capital return signal strong operational momentum and confidence in sustained growth.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 44.9% of the 303 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.26%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CAH was trading at $248.67 on NYSE in the Trade & Services sector, with a market capitalization of approximately $55.5B. The 52-week trading range was $137.75 to $244.87. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.